ONCAlert | Upfront Therapy for mRCC

Multiple Myeloma VIEW MORE >>

A supplemental Biologics License Application for daratumumab in combination with carfilzomib and dexamethasone was submitted to the FDA for consideration as treatment for relapsed/refractory multiple myeloma, according to a press release from Janssen Pharmaceuticals.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.